These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18575908)

  • 21. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
    Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study.
    Chiong F; Wasef MS; Liew KC; Cowan R; Tsai D; Lee YP; Croft L; Harris O; Gwini SM; Athan E
    BMC Infect Dis; 2021 Jul; 21(1):671. PubMed ID: 34243714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors and outcome of community onset Pseudomonas aeruginosa bacteraemia in two Malaysian district specialist hospitals.
    Tan TL; Tan-Loh J; Chiew SC; Lim KH; Ng WW; Akmal M; Khor SH; Lee LY
    Med J Malaysia; 2021 Nov; 76(6):820-827. PubMed ID: 34806667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
    Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
    Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor?
    Chen SC; Lawrence RH; Byth K; Sorrell TC
    Med J Aust; 1993 Nov; 159(9):592-7. PubMed ID: 8232033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the therapeutic efficacies of third-generation cephalosporins and broader-spectrum β-lactams as appropriate empirical therapy in adults with community-onset monomicrobial Enterobacteriaceae bacteraemia: a propensity score matched analysis.
    Lee CH; Hsieh CC; Hong MY; Hung YP; Ko WC; Lee CC
    Int J Antimicrob Agents; 2017 May; 49(5):617-623. PubMed ID: 28315452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
    Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular epidemiological survey of the quinolone- and carbapenem-resistant genotype and its association with the type III secretion system in Pseudomonas aeruginosa.
    Ferreira ML; Dantas RC; Faria ALS; Gonçalves IR; Silveira de Brito C; Queiroz LL; Gontijo-Filho PP; Ribas RM
    J Med Microbiol; 2015 Mar; 64(Pt 3):262-271. PubMed ID: 25596115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia.
    Park SY; Park HJ; Moon SM; Park KH; Chong YP; Kim MN; Kim SH; Lee SO; Kim YS; Woo JH; Choi SH
    BMC Infect Dis; 2012 Nov; 12():308. PubMed ID: 23157735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and outcomes of Klebsiella pneumoniae bacteraemia in Hong Kong.
    Pau CK; Ma FF; Ip M; You JH
    Infect Dis (Lond); 2015 May; 47(5):283-8. PubMed ID: 25697339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.
    Torres A; Cillóniz C; Ferrer M; Gabarrús A; Polverino E; Villegas S; Marco F; Mensa J; Menéndez R; Niederman M
    Eur Respir J; 2015 May; 45(5):1353-63. PubMed ID: 25614173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study.
    Lee CC; Hsieh CC; Yang CY; Hong MY; Lee CH; Tang HJ; Ko WC
    Int J Antimicrob Agents; 2019 Aug; 54(2):176-183. PubMed ID: 31108223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
    Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
    J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics and risk factors for mortality in children with Pseudomonas aeruginosa bacteraemia: A retrospective review at a paediatric tertiary centre.
    Kishimoto K; Kasai M; Kawamura N; Otake S; Hasegawa D; Kosaka Y
    J Paediatr Child Health; 2021 Dec; 57(12):1976-1980. PubMed ID: 34169605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.
    Recio R; Mancheño M; Viedma E; Villa J; Orellana MÁ; Lora-Tamayo J; Chaves F
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant Pseudomonas aeruginosa.
    Cillóniz C; Gabarrús A; Ferrer M; Puig de la Bellacasa J; Rinaudo M; Mensa J; Niederman MS; Torres A
    Chest; 2016 Aug; 150(2):415-25. PubMed ID: 27060725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
    Peña C; Suarez C; Gozalo M; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1265-72. PubMed ID: 22155832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.